HK1169318A1 - 靶向性免疫綴合物 - Google Patents
靶向性免疫綴合物Info
- Publication number
- HK1169318A1 HK1169318A1 HK12110035.2A HK12110035A HK1169318A1 HK 1169318 A1 HK1169318 A1 HK 1169318A1 HK 12110035 A HK12110035 A HK 12110035A HK 1169318 A1 HK1169318 A1 HK 1169318A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- targeted immunoconjugates
- immunoconjugates
- targeted
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23458409P | 2009-08-17 | 2009-08-17 | |
EP10162410 | 2010-05-10 | ||
PCT/EP2010/061810 WO2011020783A2 (en) | 2009-08-17 | 2010-08-13 | Targeted immunoconjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1169318A1 true HK1169318A1 (zh) | 2013-01-25 |
Family
ID=43033282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12110035.2A HK1169318A1 (zh) | 2009-08-17 | 2012-10-11 | 靶向性免疫綴合物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8945571B2 (zh) |
EP (1) | EP2467165B1 (zh) |
JP (1) | JP5764127B2 (zh) |
KR (2) | KR20120053042A (zh) |
CN (1) | CN102573922B (zh) |
AR (1) | AR077879A1 (zh) |
AU (1) | AU2010285071A1 (zh) |
CA (1) | CA2769619C (zh) |
CO (1) | CO6430436A2 (zh) |
CR (1) | CR20120042A (zh) |
EC (1) | ECSP12011685A (zh) |
ES (1) | ES2534085T3 (zh) |
HK (1) | HK1169318A1 (zh) |
IL (1) | IL217844A0 (zh) |
MA (1) | MA33717B1 (zh) |
MX (1) | MX2012002014A (zh) |
PE (1) | PE20120630A1 (zh) |
RU (1) | RU2583876C2 (zh) |
SG (1) | SG178443A1 (zh) |
TW (1) | TW201119672A (zh) |
WO (1) | WO2011020783A2 (zh) |
ZA (1) | ZA201200767B (zh) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5992710A (ja) * | 1982-11-16 | 1984-05-29 | 関西電力株式会社 | 直接水冷線路の立坑部の布設方法 |
WO2011040973A2 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
AU2015213405B2 (en) * | 2010-08-13 | 2017-08-03 | Roche Glycart Ag | Anti-FAP antibodies and methods of use |
CA2806640A1 (en) * | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use |
NO2603530T3 (zh) | 2010-08-13 | 2018-04-07 | ||
CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
KR20130118941A (ko) | 2011-02-10 | 2013-10-30 | 로슈 글리카트 아게 | 면역치료법 |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
WO2013026832A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Anti-mcsp antibodies |
CA2849033C (en) * | 2011-09-26 | 2020-05-05 | Philogen S.P.A. | Immunocytokine combination therapy |
JP6416628B2 (ja) | 2012-01-20 | 2018-10-31 | ブイアイビー ブイゼットダブリュVib Vzw | 標的変異体αヘリックスバンドルサイトカイン |
US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
JP6290209B2 (ja) * | 2012-08-07 | 2018-03-07 | ロシュ グリクアート アーゲー | 低下した及び増加したエフェクター機能を有するように操作された2つの抗体を含む組成物。 |
MA20150232A1 (fr) | 2012-08-08 | 2015-07-31 | Roche Glycart Ag | Protéines de fusion de l'interleukine-10 et leurs utilisations |
CA2878626A1 (en) | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
WO2014043523A1 (en) | 2012-09-14 | 2014-03-20 | The Johns Hopkins University | Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
CN105705641B (zh) | 2013-07-18 | 2021-07-13 | 弗拉芒区生物技术研究所 | 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 |
KR102275090B1 (ko) * | 2013-07-19 | 2021-07-09 | 브이아이비 브이지더블유 | 표적화된 변형된 il-1 패밀리 구성원 |
ES2686668T3 (es) | 2013-07-19 | 2018-10-19 | Vib Vzw | Miembros de la familia TNF modificados dirigidos |
CN105658669A (zh) | 2013-07-19 | 2016-06-08 | 弗拉芒区生物技术研究所 | 细胞因子拮抗剂的靶向 |
EP3035938B1 (en) | 2013-09-10 | 2020-08-19 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
JP2017505777A (ja) | 2014-01-29 | 2017-02-23 | シンタ ファーマスーティカルズ コーポレーション | 標的化治療薬 |
CN106456795A (zh) * | 2014-03-03 | 2017-02-22 | 辛塔医药品有限公司 | 靶向治疗学 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
MA39483A (fr) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
US10308697B2 (en) | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
KR102588377B1 (ko) | 2014-11-14 | 2023-10-12 | 에프. 호프만-라 로슈 아게 | Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자 |
GB201500875D0 (en) * | 2015-01-19 | 2015-03-04 | Philogen Spa | Antibodies for treatment and diagnosis |
JP7028643B2 (ja) * | 2015-02-13 | 2022-03-02 | エージェンシー フォー サイエンス, テクノロジー アンド リサーチ | 膜を破壊しないp53活性化ステープルペプチド |
CN114751989A (zh) * | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
AU2016329120B2 (en) * | 2015-10-02 | 2023-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory TNF receptor |
US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
UY37003A (es) | 2015-12-04 | 2017-06-30 | Novartis Ag | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion |
CN106349393B (zh) * | 2015-12-21 | 2020-10-30 | 合肥立方制药股份有限公司 | 一种增强抗体药物稳定性的结构 |
ES2877568T3 (es) | 2016-02-05 | 2021-11-17 | Orionis Biosciences Nv | Agentes de unión de Clec9A |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
CN109689087B (zh) | 2016-05-13 | 2023-04-04 | 奥里尼斯生物科学私人有限公司 | 靶向性突变干扰素-β及其用途 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
KR102050463B1 (ko) | 2016-08-10 | 2019-11-29 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
KR20190092371A (ko) * | 2016-09-21 | 2019-08-07 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 섬유아세포 활성화 단백질을 표적화하는 최적화된 합성 컨센서스 면역원성 조성물 |
IL310865A (en) | 2016-10-17 | 2024-04-01 | Pfizer | Antibodies against EDB and antibody-drug conjugates |
US11084859B2 (en) | 2016-10-24 | 2021-08-10 | Orionis Biosciences BV | Targeted mutant interferon-gamma and uses thereof |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
CA3041279A1 (en) | 2016-11-28 | 2018-05-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding domain, and polypeptide including conveying section |
CN108250302A (zh) | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多功能蛋白质 |
US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
EP3580230A1 (en) * | 2017-02-07 | 2019-12-18 | VIB vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
WO2018184965A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
ES2928718T3 (es) | 2017-04-03 | 2022-11-22 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15 |
CA3058279A1 (en) | 2017-04-13 | 2018-10-18 | F.Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
CA3067463A1 (en) | 2017-06-20 | 2018-12-27 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
EP3641647A4 (en) | 2017-06-20 | 2021-05-05 | Madrigal Pharmaceuticals, Inc. | TARGETED THERAPEUTICS |
WO2019028316A1 (en) | 2017-08-03 | 2019-02-07 | Amgen Inc. | INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT |
JP7347899B2 (ja) | 2017-08-09 | 2023-09-20 | オリオンズ バイオサイエンス インコーポレイテッド | Cd8結合物質 |
CN111328286A (zh) | 2017-08-09 | 2020-06-23 | 奥里尼斯生物科学有限公司 | Pd-1和pd-l1结合剂 |
MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
UY38074A (es) * | 2018-02-09 | 2019-10-01 | Philogen Spa | Composiciones de edb que se dirigen a il-12 |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
CN112513276B (zh) * | 2018-07-30 | 2024-03-15 | 张晋宇 | 蛋白质异二聚体及其用途 |
EP3847242A4 (en) * | 2018-09-07 | 2022-06-08 | NantBio, Inc. | TARGETED IL-12 TREATMENTS AND METHODS TO STIMULATE HANK AND NK92MI CELLS |
AU2019366956A1 (en) | 2018-10-23 | 2021-05-20 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
RU2708558C1 (ru) * | 2018-12-13 | 2019-12-09 | Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ | Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4 |
JP2022534837A (ja) | 2019-03-28 | 2022-08-04 | オリオニス バイオサイエンシズ,インコーポレイテッド | 治療用インターフェロンアルファ1タンパク質 |
AU2020285636A1 (en) * | 2019-05-24 | 2021-11-04 | Proviva Therapeutics (Hong Kong) Limited | IL-2 compositions and methods of use thereof |
TW202115115A (zh) | 2019-07-02 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 免疫結合物 |
CA3148121A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Materials and methods for improved single chain variable fragments |
KR20230004494A (ko) | 2020-04-15 | 2023-01-06 | 에프. 호프만-라 로슈 아게 | 면역접합체 |
JP2023526282A (ja) | 2020-05-13 | 2023-06-21 | ボナム セラピューティクス,インク. | タンパク質複合体の組成物及びその使用方法 |
PE20232045A1 (es) | 2020-12-04 | 2023-12-27 | Hoffmann La Roche | Polipeptidos de interleucina-2 mutante dependientes del ph |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
JP2024512382A (ja) | 2021-03-09 | 2024-03-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1標的化il-2バリアント免疫コンジュゲートと抗tyrp1/抗cd3二重特異性抗体の併用療法 |
JP2024508949A (ja) | 2021-03-09 | 2024-02-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1標的化il-2変異体イムノコンジュゲートとfap/4-1bb結合分子との併用療法 |
WO2023062050A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
WO2023094569A1 (en) | 2021-11-26 | 2023-06-01 | F. Hoffmann-La Roche Ag | Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies |
WO2023131611A1 (en) * | 2022-01-04 | 2023-07-13 | Philogen S.P.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
ATE207366T1 (de) * | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
ATE433998T1 (de) * | 1997-03-05 | 2009-07-15 | Us Health | Divalent anti-t-zellen immuntoxinen und deren verwendung |
ES2590912T3 (es) * | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
PT1257297E (pt) | 2000-02-24 | 2006-12-29 | Philogen Spa | Composições e método para tratamento da angiogénese em lesões patológicas |
AU4976001A (en) * | 2000-03-30 | 2001-10-15 | Dyax Corp | Mucin-1 specific binding members and methods of use thereof |
RU2272644C2 (ru) * | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
CN101146909A (zh) | 2005-03-25 | 2008-03-19 | 格黎卡特生物技术股份公司 | 针对MCSP的并且具有增加的Fc受体结合亲和性和效应子功能的抗原结合分子 |
CN101258162A (zh) * | 2005-05-11 | 2008-09-03 | 菲罗根股份公司 | 抗纤连蛋白ed-b和白细胞介素12的抗体l19的融合蛋白 |
US8744844B2 (en) * | 2007-07-06 | 2014-06-03 | Audience, Inc. | System and method for adaptive intelligent noise suppression |
KR20090008467A (ko) | 2006-05-08 | 2009-01-21 | 필로겐 에스.피.에이. | 치료용의 항체표적 사이토카인 |
CA2695382A1 (en) * | 2007-08-01 | 2009-02-05 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of | A fold-back diabody diphtheria toxin immunotoxin and methods of use |
BRPI0921586A2 (pt) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
-
2010
- 2010-08-13 AU AU2010285071A patent/AU2010285071A1/en not_active Abandoned
- 2010-08-13 AR ARP100102987A patent/AR077879A1/es unknown
- 2010-08-13 WO PCT/EP2010/061810 patent/WO2011020783A2/en active Application Filing
- 2010-08-13 JP JP2012525147A patent/JP5764127B2/ja active Active
- 2010-08-13 RU RU2012110127/10A patent/RU2583876C2/ru active
- 2010-08-13 CN CN201080046453.8A patent/CN102573922B/zh active Active
- 2010-08-13 MX MX2012002014A patent/MX2012002014A/es active IP Right Grant
- 2010-08-13 ES ES10744911.8T patent/ES2534085T3/es active Active
- 2010-08-13 PE PE2012000192A patent/PE20120630A1/es not_active Application Discontinuation
- 2010-08-13 CA CA2769619A patent/CA2769619C/en active Active
- 2010-08-13 EP EP10744911.8A patent/EP2467165B1/en active Active
- 2010-08-13 KR KR1020127006987A patent/KR20120053042A/ko active Application Filing
- 2010-08-13 KR KR1020157019073A patent/KR101588598B1/ko active IP Right Grant
- 2010-08-13 SG SG2012010690A patent/SG178443A1/en unknown
- 2010-08-16 TW TW099127335A patent/TW201119672A/zh unknown
- 2010-08-17 US US12/857,882 patent/US8945571B2/en active Active
-
2011
- 2011-12-29 CO CO11181029A patent/CO6430436A2/es not_active Application Discontinuation
-
2012
- 2012-01-20 CR CR20120042A patent/CR20120042A/es unknown
- 2012-01-30 MA MA34588A patent/MA33717B1/fr unknown
- 2012-01-30 IL IL217844A patent/IL217844A0/en unknown
- 2012-01-31 ZA ZA2012/00767A patent/ZA201200767B/en unknown
- 2012-02-16 EC ECSP12011685 patent/ECSP12011685A/es unknown
- 2012-10-11 HK HK12110035.2A patent/HK1169318A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AR077879A1 (es) | 2011-09-28 |
US8945571B2 (en) | 2015-02-03 |
ECSP12011685A (es) | 2012-03-30 |
CN102573922B (zh) | 2015-08-05 |
US20110064751A1 (en) | 2011-03-17 |
CN102573922A (zh) | 2012-07-11 |
ES2534085T3 (es) | 2015-04-17 |
AU2010285071A1 (en) | 2012-02-02 |
KR20120053042A (ko) | 2012-05-24 |
IL217844A0 (en) | 2012-03-29 |
TW201119672A (en) | 2011-06-16 |
EP2467165B1 (en) | 2015-01-07 |
JP2013502209A (ja) | 2013-01-24 |
WO2011020783A2 (en) | 2011-02-24 |
CR20120042A (es) | 2012-03-22 |
WO2011020783A3 (en) | 2011-04-28 |
KR101588598B1 (ko) | 2016-01-29 |
PE20120630A1 (es) | 2012-05-26 |
MX2012002014A (es) | 2012-06-13 |
CA2769619C (en) | 2019-04-30 |
ZA201200767B (en) | 2014-07-30 |
RU2012110127A (ru) | 2013-09-27 |
CO6430436A2 (es) | 2012-04-30 |
KR20150088328A (ko) | 2015-07-31 |
RU2583876C2 (ru) | 2016-05-10 |
CA2769619A1 (en) | 2011-02-24 |
EP2467165A2 (en) | 2012-06-27 |
SG178443A1 (en) | 2012-04-27 |
JP5764127B2 (ja) | 2015-08-12 |
MA33717B1 (fr) | 2012-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1169318A1 (zh) | 靶向性免疫綴合物 | |
IL252864A0 (en) | Target-targeted pyrrolobenzodiazepine conjugates | |
ZA201202612B (en) | Combination | |
IL216719A0 (en) | Pure-peg-lipid conjugates | |
GB0918579D0 (en) | Gadd45beta targeting agents | |
IL220526A0 (en) | Kokumi-imparting agent | |
EP2478768A4 (en) | ANTIPHYTOVIRAL AGENT | |
IL220527A0 (en) | Kokumi-imparting agent | |
IL219103A0 (en) | Combination | |
IL219786A0 (en) | Combination | |
ZA201202494B (en) | Combination | |
ZA201202173B (en) | Combination | |
EP2433502A4 (en) | AGENT FOR REMOVING AMERTUME | |
ZA201202495B (en) | Combination | |
ZA201202258B (en) | Combination | |
EP2406304A4 (en) | ANTHRACYCLINE-LIPID CONJUGATES WITH GABA BINDING | |
IL218801A0 (en) | Combination | |
AP2685A (en) | Sulfamoyl-phenyl-ureido benzamidine-derivatives asantimalarial agents | |
GB0906023D0 (en) | Insulin-Nanoparticle conjugates | |
GB0912975D0 (en) | Formulations | |
GB0916633D0 (en) | Cultivator | |
GB0906696D0 (en) | Combination | |
GB0901391D0 (en) | Combination | |
GB0921334D0 (en) | Preferred combination | |
GB0917744D0 (en) | Formulations |